Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Extremely large outlier treatment effects may be a footprint of bias in trials from less developed countries: randomized trials of gabapentinoids JOURNAL OF CLINICAL EPIDEMIOLOGY Desai, K., Carroll, I., Asch, S., Hernandez-Boussard, T., Ioannidis, J. A. 2019; 106: 80–87
View details for DOI 10.1016/j.jclinepi.2018.10.012
View details for Web of Science ID 000457818700010